Bolte Axel
SEC insider (Form 3/4/5 filer). CIK 0001579247. Director at Inozyme Pharma, Inc. (INZY). 5 reported Form 4/5 transactions since Sep 2024; latest on Jul 1, 2025. Located in BOSTON, MA.
Companies Bolte Axel has filed insider reports for
- Inozyme Pharma, Inc. (INZY): Director
Bolte Axel
CIK: 0001579247
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)2 (40.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)3 (60.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
INZY
Inozyme Pharma, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jul 1, 2025INZY
Inozyme Pharma, Inc.
Tender OfferDirect423.9K shares at avg. $4.00$1.7M - Jul 1, 2025INZY
Inozyme Pharma, Inc.
DispositionDirectStock Option (Right to Buy)
234.2K shares- - Jul 1, 2025INZY
Inozyme Pharma, Inc.
DispositionDirectStock Option (Right to Buy)
159.2K shares- - May 15, 2025INZY
Inozyme Pharma, Inc.
ExerciseDirect152.8K shares at avg. $0.98$150K - May 15, 2025INZY
Inozyme Pharma, Inc.
ExerciseDirect4.4K shares at avg. $0.98$4K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | Tender Offer | 423,926 | $4.00 | $1,695,704 | Direct |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | Disposition Stock Option (Right to Buy) | 234,176 | - | - | Direct |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | Disposition Stock Option (Right to Buy) | 159,187 | - | - | Direct |
| May 15, 2025 | INZY Inozyme Pharma, Inc. | Exercise | 152,823 | $0.98 | $149,767 | Direct |
| May 15, 2025 | INZY Inozyme Pharma, Inc. | Exercise | 4,407 | $0.98 | $4,319 | Direct |
1-5 of 5 transactions